Clinical trial

Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)

Name
2019-UROMUNEINM-EU
Description
An Expanded Access Program for UROMUNE® for patients suffering from recurrent/chronic urinary tract infections of diverse etiology. This is for individuals for whom antibiotic therapy has failed, but of consideration in all cases, taking into account antibiotic-induced adverse reactions and increasing antibiotic resistance.
Trial arms
Treatment
Uromune
2 sprays of solution once daily for a total of 3 months.
Other names:
MV140
Size
-1
Eligibility criteria
Inclusion Criteria: * Patients suffering recurrent urinary tract infections of diverse etiology. Exclusion Criteria: * Individuals being allergic to any of the ingredients of UROMUNE®. * Pregnancy and breast feeding. There are neither specific studies nor a formal contraindication, the physician should value benefits/risk.
Protocol
{'studyType': 'EXPANDED_ACCESS'}
Updated at
2023-09-29

1 organization

1 product

3 indications

Organization
Impatients
Product
Uromune